GlassScriptPhysician profile
John S Bivona
NPI 1740338904
$18,354.45
in general payments reported to CMS, 2019-2025
68 companies · $2,950 in 2025
The $2,950 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,535 · 2020: $2,411 · 2021: $2,897 · 2022: $2,569 · 2023: $2,431 · 2024: $2,562 · 2025: $2,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,943.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,082.75 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,849.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,185.19 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,007.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $833.25 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $686.91 | 2019-2025 | Trintellix |
| Pfizer INC. | $684.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $680.72 | 2019-2025 | Xifaxan |
| Allergan, INC. | $645.72 | 2019-2020 | |
| Esperion Therapeutics, INC. | $555.78 | 2020-2025 | Nexletol |
| Exact Sciences Corporation | $531.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $466.52 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $460.89 | 2019-2023 | Xarelto |
| Vanda Pharmaceuticals INC. | $448.57 | 2024-2025 | Fanapt |
| Antares Pharma, INC. | $395.31 | 2022-2025 | Xyosted, Tlando, Nocdurna |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $348.51 | 2019-2025 | Jardiance, Zepbound |
| Amgen INC. | $346.79 | 2019-2025 | Krystexxa, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.18 | 2019-2024 | Jardiance |
| Horizon Therapeutics Plc | $331.61 | 2019-2023 | Krystexxa |
| Ardelyx, INC. | $317.10 | 2023-2025 | Ibsrela |
| Grifols USA, LLC | $316.46 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.43 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $294.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $276.90 | 2019-2024 | Verquvo, Vaxelis, Vaxneuvance |
| Astellas Pharma US INC | $204.13 | 2019-2024 | Veozah |
| Collegium Pharmaceutical, INC. | $184.79 | 2019-2021 | |
| Corium, LLC | $172.36 | 2023-2025 | Azstarys |
| Corcept Therapeutics | $158.12 | 2019-2025 | Korlym |
| Tolmar, INC. | $149.59 | 2023-2025 | Jatenzo |
| Nuvasive, INC. | $146.13 | 2022 | |
| Halozyme INC | $142.63 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $126.25 | 2021-2022 | |
| Tris Pharma INC | $105.77 | 2024-2025 | Dyanavel Xr |
| Eisai INC. | $104.37 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $91.05 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $85.79 | 2019-2020 | |
| Daiichi Sankyo INC. | $83.01 | 2019 | |
| Scilex Pharmaceuticals INC. | $80.15 | 2021-2024 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $71.42 | 2020-2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $63.64 | 2021-2022 | |
| Redhill Biopharma INC. | $56.40 | 2021-2022 | |
| Axsome Therapeutics, INC. | $53.61 | 2025 | Auvelity |
| Arbor Pharmaceuticals, INC. | $51.73 | 2020-2021 | |
| Almatica Pharma LLC | $51.51 | 2021-2022 | |
| Shield Therapeutics INC | $50.30 | 2023-2025 | Accrufer |
| Lundbeck LLC | $49.89 | 2025 | Rexulti |
| Abbott Laboratories | $49.88 | 2021-2023 | Freestyle Libre 2 |
| Aytu Biopharma, INC. | $48.99 | 2020 | |
| Alkermes, INC. | $45.42 | 2022-2023 | Aristada, Lybalvi |
| Dexcom, INC. | $44.26 | 2021-2025 | Dexcom G6 Transmitter |
| Biodelivery Sciences International, INC. | $42.85 | 2019 | |
| Supernus Pharmaceuticals, INC. | $33.91 | 2025 | Xyosted, Tlando, Qelbree |
| Genentech USA, INC. | $30.16 | 2019 | |
| Intra-Sana Laboratories | $26.31 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Verity Pharmaceuticals INC. | $25.92 | 2025 | Tlando |
| Kowa Pharmaceuticals America, INC. | $25.69 | 2020-2022 | |
| Hologic Sales and Service, LLC | $23.31 | 2019 | |
| Kyowa Kirin, INC. | $21.70 | 2024 | Crysvita |
| Shire North American Group INC | $18.06 | 2019 | |
| Evoke Pharma, INC. | $15.70 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.66 | 2020 | |
| Currax Pharmaceuticals LLC | $14.61 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.78 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.46 | 2021 | |
| Adlon Therapeutics L.P. | $13.23 | 2020 | |
| Mdd US Operations, LLC | $13.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bivona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.